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INTRODUCTION
The acquired immunodeficiency syndrome (AIDS) is caused by the human immuno-
deficiency virus (HIV), a retrovirus that preferentially infects CD4 lymphocytes and lead to
profound deficit in cellular immunity. The present HIV epidemic in Uganda is as severe as
anywhere in the world. Among the total population of twenty million people, approximately
two hundred people are estimated to be infected with HIV-1. This disease is, therefore,
seriously affecting the Ugandan society. Compromised immunesystem renders HIV-infected
adults more susceptible to a wide variety of pathogens. The paptients with AIDS in Uganda
are highly associated with opportunistic infection such as tuberculosis (TB), cryptococcal
meningitis and others.
We, the Department of Internal Medicine, exchanged the memorandomfor the col-
laborative studies with Makerere University in 1991, because the Dean of the Faculty of
Medicine, Mekerere University in Uganda visited our institute in 1989 and strongly requested
for cooperation on the HIV/AIDS related studies. We, therefore, started the collaborative
studies on AIDS-related opportunistic infections from 1993.
The purpose of the collaborative studies is to support the diagnosis and treatment of
HIV/AIDS associated opportunistic infections in Mulago Hospital, Makerere University. We
have already developed three projects on major opportunistic infections among HIV-infected
Ugandan adult. First, we developed a study for cryptococcal meningitis in AIDS paptients.
We, next, developed a study on the treatment of pulmonary tuberculosis in HIV-infected
persons. Finally, we carried out a study on community-acquired pneumonia. Weintroduce the
studies on cryptococcal meningitis and community-acquired pneumonia.
Diagnosis and treatment of cryptococcal meningitis in patients with AIDs in
Uganda
Cryptococcal meningitis is the most commoninvasive fungal infection in patients with
AIDS, occuring in up to 30% in sub-Saharan Africa. This disease is regarded as a life-
threatening opportunistic infection particularly in Africa. Fluconazole, one of the recently
developed triazole antifungal drugs, shows a promising effect in the treatment of cryptococcal
meningitis in patients with AIDS. To establish the easily-managed and cost-effective an-
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ticryptococcal therapy for AIDS-associated cryptococcal meningitis in developing countries,
this study was designed to compare the effects of treatment with low-dose oral fluconazole
and short-term flucytosine with that of fluconazole alone (1). This study was developed from
January to December in 1994. HIV seropositive patients over 16 years old were enrolled, if
they presented cryptococcal meningitis-like symptoms and positive for cryptococcal staining
or antigen in cerebrospinal fluid.
30 of 58 patients were randomized to receive combination therapy, and 28 were ran-
domized to receive fluconazole monotherapy. Before treatment, almost all of the patients had
headache, described as severe by 91% of patients. Half of the patients showed decreased
consciousness. With respect to opportunistic infections other than cryptococcal meningitis,
oral candidiasis was most frequently observed in 69%, and pulmonary tuberculosis was di-
agnosed in 9%. The mean CD4 and CDS peripheral blood counts were 77 and 208/m.a
respectively. There was no significant differences with respect to demographic characteris-
tics, laboratory values, or clinical symptoms and sign between the treatment group at base-
line.
Wecould evaluate the survival rate of 50 patients at the end point of primary therapy
and maintenance therapy for six months (Figure 1). Ten out of 25 patients receiving the
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Figure 1. Survival of AIDS patients with cryptococcal meningitis during
oral fluconazole with or without flucytosine in Uganda FLCZ-
fluconazole, 5FC; flucytosine.
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of these patients (36%) survived for two months. In contrast, the combination therapy
reduced the early deaths among these patients during the first two weeks, and 14 of 25
patients assigned to the combination therapy survived the full two months of initial therapy.
At the end of the primary and maintenance therapy for 6 months, the survival rate of 25
patients receiving the combination therapy (32%) was significantly higher than that (12%) of
the 25 patients assigned to the monotherapy. Despite the improved survival rate in patients
receiving the combination therapy, the rate of positive cryptococcal cultures in cerebrospinal
fluid remained high at 2 months and 6 months post-treatment, respectively. These data in-
dicated that a large proportion of the patients had quiescent disease both at the end point of
primary and maintenance therapy. No serious adverse effects were noted in any of the en-
rolled patients during the primary or maintenance therapy.
These data support that treatment with fluconazole is a cost-effective and safe regimen
that improve the quality of life for patients with associated cryptococcal meningitis in HIV-
epidemic developing countries. We, however, have the following problems. First, we still
have a high mortality despite oral anti-cryptococcal drugs. Second, the total management of
the treatment for cryptococcal meningitis in AIDS patients is difficult. Third, it is expensive
to supply the adequate antifungal chemotherapy.
Diagnosis and treatment of community-acquired pneumonia among Ugandan
adults
In tropical and developing countries at least one third of deaths are due to pulmonary
infections. Before the outbreak of HIV infection in Africa, Streptococcus pneumoniae (S. pneu-
moniae) was reported to be only one predominant pathogen of acute pneumonia. However,
clinical and microbilogical characteristics for community-acquirred pneumonia in HIV-
seropositive patients in Africa have not fully investigated. In this study, we evaluated clinical
and microbiological features, and clinical effectiveness by ampicillin therapy for community-
acquired pneumonia amongUgandan adults particularly in the respect to HIV infection (2).
The study was done from 1996 to March 1998. Patients over 16 years old were enrolled
if they were confirmed to have acute pneumonia by clinical symptoms and findings of chest
radiograph. Quantitative culture method on rabbit blood agar and Gram's staining for freshly
expectorated sputum was used for microbiological diagnosis.
More interestingly, 72.5% of 91 patients with community acquired pneumonia were in-
fected with HIV-1. Their mean CD4 peripheral-blood counts and CD4/CD8 ratio were 330/
mm3and 0.48, and these were significantly lower than those in HIV-seronegative patients. For
severity of community-acquired pneumonia, there was no difference in respiratory rates, pulse
oxymetry oxygen saturation (Sp02), extent of pneumonia on chest radiograph, and other in-
flammatory data between HIV-seropositive and HIV-seronegative patients at baseline.
Causative pathogens were determined by sputum or blood samples in 45 cases. Similar
pattern of causative respiratory pathogens were identified in both groups, and major patho-
gens were S. pneumoniae, H. influenzae, Moraxella catarrhalis, Staphylococcus aureus and
Klebsiella pneumoniae.
Parental ampicillin therapy followed by oral amoxicillin for one weeks was given im-
mediately after enrollment. Clinical effectiveness was evaluated by improvement of clinical
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symptoms and signs, and laboratory markers, and chest radiographs. We found 15 cases of
fair and poor responders in HIV-seropositive individuals, while there was only one fair
responder in HIV-seronegative individuals. More importantly, the mean CD4 pepripheral
blood cell counts in the fair and poor responders were lower than those in good responder in
HIV-seropositive patients.
These data support that a large part of patients with community-acquired pneumonia in
Uganda were infected with HIV-1. No difference of causative pathogens was noted between
HIV-seropositive and HIV-seronegative patients. HIV-1 associated immune suppression ap-
peared to decrease the clinical effectiveness of ampicillin therapy for community-acquired
penumonia. These data indicate that bacteriological diagnosis and careful antibiotic therapy
are required for patients with community-acquired pneumonia.
Present situation of the collaborative studies
As introduced here, we have successfully carried out collaborative studies on treatment
of HIV/AIDS related opportunistic infections during the last seven years. We feel that more
training of physicians or technicians are necessary for the high quality studies. Although we
obtained the meaningful results in our collaborative study, how the knowledges and ex-
periences from these studies are utilized for the clinical practice in the study place?
Nevertheless, the published data may attract the attention for researchers or clinicians
inside and outside of Uganda. These secondary benefits may increase global recognition of
medical needs in specific area and may change the priorities of governmental agencies, as
quoted in editorial response of a certain journal (1).
Future prospects of the collaborative studies
What is the future prospects and the goal of our collaborative studies? Not only to
produce the data, but also to integrate the knowledge or technology into the training in
special field of studies is important. Their knowledge and experiences could be utilized for
future projects and clinical practice in Uganda. It is also possible to develop basic studies on
infectious diseases in tropical area in certain research center in Uganda.
In summary,these processes of collaborative studies may produce fruitful results which
contributes to the clinical practice in Uganda, and promote to obtain the government supports
for specific infectious diseases.
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